Cryoport, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Cryoport, Inc. on April 2, 2015, covering events occurring between March 20, 2015, and March 31, 2015. The filing details a private placement of securities to institutional and accredited investors.
Key Financial Metrics and Transaction Details
- Transaction Period: March 20, 2015 to March 31, 2015.
- Aggregate Gross Proceeds (through March 31): $1.9 million.
- Net Proceeds (estimated): Approximately $1.7 million after offering costs.
- Securities Issued: 161,709 shares of Class B Preferred Stock and warrants to purchase 1,293,672 shares of Common Stock.
- Warrant Terms: Exercise price of $0.50 per share; exercisable immediately through May 31, 2020.
- Unit Price: $12.00 per Unit (one share of Preferred Stock plus one warrant for eight shares of Common Stock).
- Placement Agent Fees: 10% commission plus a 3% non-accountable finance fee on gross proceeds, plus up to $5,000 in legal expense reimbursement.
- Use of Proceeds: Working capital purposes.
Material Changes and Offering Status
The company entered into definitive Subscription Agreements for the private placement. While the initial reporting window covered March 20 to March 31, the company and the placement agent, Emergent Financial Group, Inc., agreed to extend the offering period through April 13, 2015. The sale was conducted under exemptions provided by Regulation D and Section 4(2) of the Securities Act of 1933.
Guidance, Risks, and Contingencies
The filing does not provide specific financial guidance, outlook, or management commentary regarding future operational performance. The primary contingency noted is the extension of the offering deadline to April 13, 2015. The filing explicitly states that the summary of terms is qualified by reference to the full text of the Subscription Agreements and warrants filed as Exhibits 10.1 and 4.1 to a prior Form 8-K filed on February 20, 2015.
Key Facts for Investor Verification
- Verify the total capital raised after the offering extension deadline of April 13, 2015.
- Review the full text of the Subscription Agreements (Exhibit 10.1) and Warrants (Exhibit 4.1) referenced in the filing for complete terms and conditions.
- Confirm the dilution impact of the 1,293,672 warrant shares exercisable at $0.50 per share.
- Monitor the company's cash burn rate to assess the sufficiency of the $1.7 million net proceeds for working capital needs.